Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhifeng Cheng

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
NEJM Evidence|June 7, 2026
HTD1801 in Combination with Metformin for Type 2 DiabetesLinong Ji, Zhifeng Cheng, Jianhua Ma, et al.
Journal of Diabetes|April 11, 2025
Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator StudyLi Liu, Zhifeng Cheng, Lianwei Wang, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialJianping Weng, Longyi Zeng, Yuwei Zhang, et al.
JAMA Network Open|March 3, 2025
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical TrialLinong Ji, Jianhua Ma, Yujin Ma, et al.
Diabetes, Obesity & Metabolism|November 26, 2022
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialLeili Gao, Zhifeng Cheng, Benli Su, et al.
Journal of Orthopaedic Translation|September 12, 2022
Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trialHanting Liang, Ou Wang, Zhifeng Cheng, et al.
Journal of the American Heart Association|May 31, 2024
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed DyslipidemiaXiaozeng Wang, Miaohan Qiu, Zhifeng Cheng, et al.
JAMA Network Open|June 3, 2026
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical TrialLixin Guo, Zilin Sun, Lihui Zhang, et al.
Atherosclerosis|June 21, 2025
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trialChunli Shao, Shu Zhang, Zhifeng Cheng, et al.
Nature Communications|December 13, 2023
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesityLinong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
NEJM Evidence|June 7, 2026
HTD1801 in Combination with Metformin for Type 2 DiabetesLinong Ji, Zhifeng Cheng, Jianhua Ma, et al.
Journal of Diabetes|April 11, 2025
Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator StudyLi Liu, Zhifeng Cheng, Lianwei Wang, et al.
Diabetes, Obesity & Metabolism|March 26, 2021
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialJianping Weng, Longyi Zeng, Yuwei Zhang, et al.
JAMA Network Open|March 3, 2025
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical TrialLinong Ji, Jianhua Ma, Yujin Ma, et al.
Diabetes, Obesity & Metabolism|November 26, 2022
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialLeili Gao, Zhifeng Cheng, Benli Su, et al.
Journal of Orthopaedic Translation|September 12, 2022
Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trialHanting Liang, Ou Wang, Zhifeng Cheng, et al.
Journal of the American Heart Association|May 31, 2024
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed DyslipidemiaXiaozeng Wang, Miaohan Qiu, Zhifeng Cheng, et al.
JAMA Network Open|June 3, 2026
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical TrialLixin Guo, Zilin Sun, Lihui Zhang, et al.
Atherosclerosis|June 21, 2025
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trialChunli Shao, Shu Zhang, Zhifeng Cheng, et al.
Nature Communications|December 13, 2023
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesityLinong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
Pageof 8